Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

United States Cytomegalovirus (CMV) Infection Market Insights, Epidemiology and Market Forecasts 2016-2023 - Research and Markets

Research and Markets
Posted on: 17 Oct 16

Research and Markets has announced the addition of the "Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast - 2023 -United States" drug pipelines to their offering.

The US market size of Cytomegalovirus (CMV) infection shall reach to USD 609.88 Million by the end of 2023. The market size for Prophylaxis is expected to grow at a CAGR of 3.71% from 2013-2023, while the sales for the therapeutic shall increase at a CAGR of 3.55% from the year 2013-2023. As per estimation, the US Prophylaxis market is relatively higher than the therapeutic market.

United States Cytomegalovirus (CMV) Infection - Market Insights, Epidemiology and Market Forecast 2023 provides an overview of the disease and market size of the CMV for United States. It also includes historical and forecasted epidemiological data for the CMV Prevalent, Diagnosed and Treatable Cases, CMV Patients among Transplants, Infants Patients at High Risk of CMV and HIV Patients at High Risk of CMV from 2013-2023.

As per estimation, the total number of Diagnosed CMV Infection cases in United States is expected to increase at a CAGR of 0.041% to 77,726 cases in 2023.

Key Topics Covered:

  1. Cytomegalovirus Infections
  2. Disease Overview
  3. Symptoms of cytomegalovirus (CMV) Infection
  4. Etiology
  5. Risk Factors
  6. Pathogenesis of human cytomegalovirus
  7. Pathophysiology of cytomegalovirus infection
  8. Diagnosis
  9. Treatment Algorithm for Cytomegalovirus Infections
  10. Treatment for Congenital CMV Infection
  11. Treatment of Ganciclovir resistant CMV
  12. Treatment Guidelines
  13. Recommendations for Treating Cytomegalovirus Infections
  14. Disease Management
  15. Epidemiology and Patient Population
  16. United States
  17. Assumptions and Rationale
  18. Total CMV Prevalent, Diagnosed and Treatable Cases
  19. CMV Patients among Transplants
  20. Infant Patients at High Risk of CMV
  21. HIV Patients at High Risk of CMV in United States
  22. Unmet Medical Needs
  23. Marketed Products

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/wr8tt4/cytomegalovirus

View source version on businesswire.com: http://www.businesswire.com/news/home/20161017005520/en/

Business Wire
www.businesswire.com

Last updated on: 17/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.